These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1582124)

  • 1. Slow-releasing nicardipine in the treatment of Raynaud's phenomena without underlying diseases.
    Ferri C; Cecchetti R; Cini G; Gambini I; La Civita L; Bernini L; Bombardieri S; Pasero G
    Clin Rheumatol; 1992 Mar; 11(1):76-80. PubMed ID: 1582124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial.
    Kahan A; Amor B; Menkès CJ; Weber S; Guérin F; Degeorges M
    Angiology; 1987 Apr; 38(4):333-7. PubMed ID: 3555175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nicardipine in the treatment of Raynaud's phenomenon].
    Kahan A; Amor B; Menkès CJ
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind placebo-controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon.
    Wollersheim H; Thien T
    J Cardiovasc Pharmacol; 1991 Dec; 18(6):813-8. PubMed ID: 1725892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm.
    Wigley FM; Wise RA; Malamet R; Scott TE
    Arthritis Rheum; 1987 Mar; 30(3):281-6. PubMed ID: 2952125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous nicardipine in Raynaud's phenomenon: a controlled trial.
    van Heereveld H; Wollersheim H; Gough K; Thien T
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):68-74. PubMed ID: 2450259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. French Cooperative Multicenter Group for Raynaud Phenomenon, Paris, France.
    Am Heart J; 1991 Jul; 122(1 Pt 2):352-5. PubMed ID: 2053556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
    Herrick AL; van den Hoogen F; Gabrielli A; Tamimi N; Reid C; O'Connell D; Vázquez-Abad MD; Denton CP
    Arthritis Rheum; 2011 Mar; 63(3):775-82. PubMed ID: 21360507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
    Chung L; Shapiro L; Fiorentino D; Baron M; Shanahan J; Sule S; Hsu V; Rothfield N; Steen V; Martin RW; Smith E; Mayes M; Simms R; Pope J; Kahaleh B; Csuka ME; Gruber B; Collier D; Sweiss N; Gilbert A; Dechow FJ; Gregory J; Wigley FM
    Arthritis Rheum; 2009 Mar; 60(3):870-7. PubMed ID: 19248104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
    Denton CP; Hachulla É; Riemekasten G; Schwarting A; Frenoux JM; Frey A; Le Brun FO; Herrick AL;
    Arthritis Rheumatol; 2017 Dec; 69(12):2370-2379. PubMed ID: 29193819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.
    Sauza J; Kraus A; González-Amaro R; Alarcón-Segovia D
    J Rheumatol; 1984 Jun; 11(3):362-4. PubMed ID: 6376801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational use of calcium-channel antagonists in Raynaud's phenomenon.
    Sturgill MG; Seibold JR
    Curr Opin Rheumatol; 1998 Nov; 10(6):584-8. PubMed ID: 9812220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.
    Lee EY; Park JK; Lee W; Kim YK; Park CS; Giles JT; Park JW; Shin K; Lee JS; Song YW; Lee EB
    Rheumatology (Oxford); 2014 Apr; 53(4):658-64. PubMed ID: 24352340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
    Correa MJ; Mariz HA; Andrade LE; Kayser C
    Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.